People who achieved sustained remission of type 2 diabetes via substantial weight loss in the DiRECT trial regained normal maximal beta-cell capacity, the investigators report.
A high volume of moderate-to-vigorous intensity exercise during the first trimester of pregnancy may reduce the risk for hyperglycemia and gestational diabetes later on, research shows.
Research presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, suggests that high-intensity exercise can partially restore counterregulatory responses to hypoglycemia in people with impaired awareness of the condition.
Researchers report that having type 1 diabetes may affect children’s brain growth and cognitive development, with persistent hyperglycemia the most likely culprit.
Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.
Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.
The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.
The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.
Oral semaglutide significantly reduces glycated hemoglobin and bodyweight versus placebo in people with type 2 diabetes that is poorly controlled on insulin, results of the PIONEER 8 study show.
Phase II findings show that the immunotherapy teplizumab significantly prolongs the time until people at very high risk for developing type 1 diabetes are diagnosed with the condition.
The PIONEER 5 and 7 trials show the efficacy of oral semaglutide in people with moderate renal impairment and the potential for a flexible dosing regimen.
Patients with type 2 diabetes last for longer before needing treatment intensification if they are treated with fixed-ratio combination insulin degludec and liraglutide rather than insulin glargine 100 U/mL, show the DUAL VIII findings.
The latest analysis from the observational follow-up of the TODAY study participants shows rapid accumulation of cardiovascular risk factors and diabetes complications in people who were diagnosed with type 2 diabetes in youth.
Data from the phase IIIa PIONEER 2 and PIONEER 4 studies show that semaglutide equals or betters both empagliflozin and liraglutide for the reduction of glycated hemoglobin in patients with type 2 diabetes uncontrolled on metformin.
High-dose vitamin D supplementation does not significantly reduce the risk for developing type 2 diabetes among people with prediabetes, show D2d trial data.
Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.
Researchers have discovered an immune cell with the attributes of both B cells and T cells, which is present in increased frequency in some people with type 1 diabetes and capable of activating insulin-specific T-helper cells.
People with type 1 diabetes who have depressive symptoms may have an increased risk for diabetic ketoacidosis as well as deteriorating glycemic control, research suggests.
Obese adults with prediabetes may need a longer-than-recommended course of behavioral weight loss treatment to optimize improvements in glycemic control, US researchers report.